Matthew Kulke

Matthew Helmut Kulke is a Professor of Medicine at the Dana–Farber/Harvard Cancer Center. His work has shed light on the molecular characteristics of neuroendocrine tumors.[1][2][3] His research has led to the development of multiple new treatments for this condition.[4] He completed his MD at UCSF School of Medicine in 1992 and completed a master's degree in medical science at Harvard Medical School.[5] He has an h-index of 55.[6]

References
  1. Chan, Jennifer A; Kulke, Matthew H (2011). "New Treatment Options for Patients with Advanced Neuroendocrine Tumors". Current Treatment Options in Oncology. 12 (2): 136–48. doi:10.1007/s11864-011-0148-2. PMID 21437592.
  2. Kulke M H; et al. (2006). "Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors". J. Clin. Oncol. 24 (22): 3555–3561. doi:10.1200/JCO.2006.05.6762. PMID 16877721.
  3. Kulke MH, et al. "A Phase 2 Study to Evaluate the Efficacy of SU11248 in Patients with Unresectable Neuroendocrine Tumors". Presented at ASCO 2005. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=33268.
  4. "2015-2016 Recently Appointed Professors" (PDF). The Faculty of Medicine - Harvard University. Retrieved 16 January 2018.
  5. "Matthew H. Kulke, MD". Dana–Farber/Harvard Cancer Center. Retrieved 16 January 2018.
  6. "kulke m". Google Scholar. Retrieved 16 January 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.